Timothy C. Guetterman

Generating author description...

All published works

Action	Title	Year	Authors
+	Community acceptability of dengue fever surveillance using unmanned aerial vehicles: A cross-sectional study in Malaysia, Mexico, and Turkey	2022	Esther Annan Jinghui Guo Aracely Ángulo-Molina Wan Fairos Wan Yaacob Nasrin Aghamohammadi Timothy C. Guetterman Sare İlknur Yavaşoğlu Kevin Bardosh Nazri Che Dom Bingxin Zhao
+ PDF Chat	A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research network	2017	Samkeliso Mawocha Michael D. Fetters Laurie J. Legocki Timothy C. Guetterman Shirley Frederiksen William G. Barsan Roger Lewis Donald A. Berry William J. Meurer
+ PDF Chat	The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project	2017	Timothy C. Guetterman Michael D. Fetters Samkeliso Mawocha Laurie J. Legocki William G. Barsan Roger Lewis Donald A. Berry William J. Meurer
+ PDF Chat	Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project	2016	William J. Meurer Laurie J. Legocki Samkeliso Mawocha Shirley M. Frederiksen Timothy C. Guetterman William G. Barsan Roger Lewis Donald A. Berry Michael D. Fetters
+ PDF Chat	Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study	2015	Timothy C. Guetterman Michael D. Fetters Laurie J. Legocki Samkeliso Mawocha William G. Barsan Roger Lewis Donald A. Berry William J. Meurer

Common Coauthors

Coauthor	Papers Together
Laurie J. Legocki	4
William J. Meurer	4
Michael D. Fetters	4
Roger Lewis	4
William G. Barsan	4
Samkeliso Mawocha	4
Donald A. Berry	4
Nasrin Aghamohammadi	1
Aracely Angulo‐Molina	1
Ubydul Haque	1
Uyen‐Sa Nguyen	1
Kevin Bardosh	1
Uriel A. López-Lemus	1
Shirley M. Frederiksen	1
Wan Fairos Wan Yaacob	1
Shirley Frederiksen	1
Latifur Khan	1
Jinghui Guo	1
Bingxin Zhao	1
Esther Annan	1
Nazri Che Dom	1
Sare İlknur Yavaşoğlu	1

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project	2012	William J. Meurer Roger J. Lewis Danilo A. Tagle Michael D. Fetters Laurie Legocki Scott Berry Jason Connor Valerie Durkalski Jordan Elm Wenle Zhao	4
+ PDF Chat	Clinical trialist perspectives on the ethics of adaptive clinical trials: a mixed-methods analysis	2015	Laurie J. Legocki William J. Meurer Shirley Frederiksen Roger Lewis Valerie Durkalski Donald A. Berry William G. Barsan Michael D. Fetters	4
+ PDF Chat	Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus	2013	Jason T. Connor Jordan Elm Kristine Broglio	3
+ PDF Chat	The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study	2015	Jason T. Connor Kristine Broglio Valerie Durkalski William J. Meurer Karen C. Johnston	3
+ PDF Chat	Adaptive trial designs: a review of barriers and opportunities	2012	John A. Kairalla Christopher S. Coffey Mitchell A Thomann Keith E. Muller	3
+ PDF Chat	Reflections on the adaptive designs accelerating promising trials into treatments (ADAPT-IT) process—Findings from a qualitative study	2015	Timothy C. Guetterman Michael D. Fetters Laurie J. Legocki Samkeliso Mawocha William G. Barsan Roger Lewis Donald A. Berry William J. Meurer	3
+	Adaptive Design: Results of 2012 Survey on Perception and Use	2014	Caroline C. Morgan Susan Huyck Martin Jenkins Li Chen Alun Bedding Christopher S. Coffey Brenda Gaydos J. Kyle Wathen	3
+ PDF Chat	Spinal Cord Injury Neuroprotection and the Promise of Flexible Adaptive Clinical Trials	2013	William J. Meurer William G. Barsan	2
+	Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development	2010	Judith Quinlan Brenda Gaydos Jeff Maca Michael Krams	2
+ PDF Chat	Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop	2012	Christopher S. Coffey Bruce Levin Christina Clark Cate Timmerman Janet Wittes Peter R. Gilbert Sara Harris	2
+ PDF Chat	Adaptive design methods in clinical trials – a review	2008	Shein‐Chung Chow Mark Chang	2
+	Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012	2014	Leonard Sacks Hala Shamsuddin Yuliya Yasinskaya Khaled Bouri Michael Lanthier Rachel E. Sherman	2
+	Uptake of novel statistical methods for early-phase clinical studies in the UK public sector	2013	Thomas Jaki	1
+	The Clinical Trials Transformation Initiative: innovation through collaboration	2014	Pamela Tenaerts Leanne K. Madre Patrick Archdeacon Robert M. Califf	1
+ PDF Chat	Travel risk, malaria importation and malaria transmission in Zanzibar	2011	Arnaud Le Menach Andrew J. Tatem Justin M Cohen Simon I Hay Heather Randell Anand P. Patil David L. Smith	1
+	Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III	2010	Zoran Antonijevic José Paulo Pinheiro Parvin Fardipour Roger Lewis	1
+ PDF Chat	Commentary on Hey and Kimmelman	2015	J. Jack Lee	1
+ PDF Chat	Are outcome-adaptive allocation trials ethical?	2015	Spencer Phillips Hey Jonathan Kimmelman	1
+ PDF Chat	The hazards of randomized phase II trials	2011	Primo N. Lara Mary W. Redman	1
+	Learning versus confirming in clinical drug development*	1997	Lewis B. Sheiner	1
+ PDF Chat	Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials	2015	Munyaradzi Dimairo Jonathan Boote Steven A. Julious J P Nicholl Susan Todd	1
+	A Regulatory View on Adaptive/Flexible Clinical Trial Design	2006	Hung Hung Robert T. O’Neill Sue‐Jane Wang John Lawrence	1
+	Adaptive Designs: Terminology and Classification	2006	Vladimir Dragalin	1
+ PDF Chat	Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data	2016	Oktay Yıldırım Matthias Gottwald Peter Schüler Martin C. Michel	1
+	Adaptive trial design: Its growing role in clinical research and implications for pharmacists	2011	Joshua Cirulli Wesley McMillian Mojdeh Saba David D. Stenehjem	1
+ PDF Chat	Risk of dengue virus infection according to serostatus in individuals from dengue endemic areas of Mexico	2020	Irma Y. Amaya-Larios Ruth Aralí Martínez-Vega Fredi Alexander Díaz-Quijano Elsa Sarti Esteban Puentes-Rosas Lilia Chihu-Amparán José Ramos-Castañeda	1
+	How large should a phase II trial of a new drug be?	1987	Ronald Simon	1
+ PDF Chat	Adaptive Designs for Clinical Trials	2016	Deepak L. Bhatt Cyrus R. Mehta	1
+ PDF Chat	Adaptive Clinical Trials: The Promise and the Caution	2010	Donald A. Berry	1
+ PDF Chat	Attitudes and opinions regarding confirmatory adaptive clinical trials: a mixed methods analysis from the Adaptive Designs Accelerating Promising Trials into Treatments (ADAPT-IT) project	2016	William J. Meurer Laurie J. Legocki Samkeliso Mawocha Shirley M. Frederiksen Timothy C. Guetterman William G. Barsan Roger Lewis Donald A. Berry Michael D. Fetters	1
+	Adaptive clinical trials in oncology	2011	Donald A. Berry	1
+	Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group	2006	Paul Gallo Christy Chuang‐Stein Vladimir Dragalin Brenda Gaydos Michael Krams José Cirı́aco Pinheiro	1
+	Adaptive designs for confirmatory clinical trials	2009	Frank Bretz Franz Koenig Werner Brannath Ekkehard Glimm Martin Posch	1
+	The future of drug development: advancing clinical trial design	2009	John J. Orloff Frank L. Douglas José Cirı́aco Pinheiro Susan L. Levinson Michael Branson Pravin Chaturvedi Ene Ette Paul Gallo Gigi Hirsch Cyrus R. Mehta	1
+ PDF Chat	Bayesian clinical trials in action	2012	J. Jack Lee Caleb T. Chu	1
+ PDF Chat	Adaptive Sample Size Calculations in Group Sequential Trials	1999	Walter Lehmacher Gernot Wassmer	1